Home › Breast Cancer › NCT05190978
Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction
Who can join
Ages 22 to 75 · Women
Full eligibility criteria
Inclusion Criteria: * Female patients age 22 to 75 undergoing unilateral or bilateral immediate pre-pectoral reconstruction with tissue expanders * Prophylactic and oncologic mastectomies are both acceptable * Nipple sparing and skin sparing mastectomy techniques are both acceptable Exclusion Criteria: * Intraoperative assessment demonstrates unfavorable conditions (ie poor mastectomy skin flap thickness or viability) for immediate pre-pectoral reconstruction in any breast * Bilateral reconstruction patients undergoing contralateral submuscular reconstruction * Direct-to-implant reconstruction * Pregnancy * Delayed reconstruction
About the study
Surgical mesh products, particularly acellular dermal matrices (ADM), are now used by the majority of plastic surgeons to assist with the nearly 100,000 prosthetic breast reconstruction procedures in the United States, despite never being approved by Food and Drug Administration (FDA) for this indication. As surgeons transition to placing breast implants above the chest muscle (pre-pectoral), there has been an increasing reliance on these often expensive mesh products without robust evidence to understand their risks and benefits. Our pilot study is a randomized multi-center trial to evaluate surgical mesh assistance in pre-pectoral tissue expander to breast implant reconstruction to address vital questions for women's public health.
What is being tested
- Acellular Dermal Matrix (device)
- Reconstruction without ADM (procedure)
Sponsor: University of California, Los Angeles · Participants: 120 · Started: Oct 20, 2022
Contact the study team
- Michael Delong, MD · Phone: (310) 825-5510
- Jaco Festekjian, MD · Phone: (310) 825-5510
Official record on ClinicalTrials.gov — NCT05190978
Locations in the U.S.
| California | University of California Los Angeles, Los Angeles |
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.